Central Nervous System-Active Medication Use in Older Adults With and Without Dementia-A Retrospective Cohort Study

被引:0
作者
Warner, Nafisseh S. [1 ,2 ,5 ]
Van Houten, Holly K. [2 ]
Tung, Ericka E. [4 ]
Verdoorn, Brandon P. [4 ]
Warner, David O. [5 ]
Mielke, Michelle M. [6 ]
Jeffery, Molly M. [2 ,3 ,7 ]
机构
[1] Mayo Clin, Dept Anesthesiol & Perioperat Med, Div Pain Med, Rochester, MN 55905 USA
[2] Mayo Clin, Kern Ctr Sci Healthcare Delivery, Rochester, MN USA
[3] OptumLabs, Eden Prairie, MN USA
[4] Mayo Clin, Dept Med, Div Community Internal Med Geriatr & Palliat Care, Rochester, MN USA
[5] Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, MN USA
[6] Wake Forest Univ, Dept Epidemiol & Prevent, Sch Med, Winston Salem, NC USA
[7] Mayo Clin, Dept Emergency Med, Rochester, MN USA
关键词
ALZHEIMER-DISEASE; UNITED-STATES; RISK;
D O I
10.1007/s11606-025-09454-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Importance: Central nervous system (CNS)-active medication use is common in older adults; however, there are limited data on utilization trends over time, differences in utilization amongst those with and without dementia, and modification of utilization surrounding dementia diagnosis. Objective: To evaluate CNS-active medication trends in US older adults with and without dementia over 13 years, including evaluation of changes in utilization before and after dementia diagnosis. Design: Retrospective observational cohort study using de-identified administrative claims data. Participants: Older adult (age >= 65 years) commercial and Medicare Advantage enrollees with continuous medical and pharmacy coverage for at least one calendar year from 2010 through 2022. Main Measures: (1) Annual probability of receiving CNS-active medications; (2) changes in medication use with dementia diagnosis. Key Results: In total, 6,062,601 enrollees were included; 682,833 (11.3%) with dementia and 5,379,768 (88.7%) without. CNS-active medication use was highest in those with dementia throughout the study time period. Opioid utilization in those with and without dementia was 36.1% and 29.6% in 2010, decreasing to 24.3% and 22.2%, respectively, in 2022. Antidepressant use increased over time (i.e., 45.2 to 52.0% dementia; 15.8 to 24.6% without). Antipsychotic use in those with dementia was 18.1% in 2010, decreased to 15.9% in 2016, and increased back to 18.0% in 2022. A total of 444,587 enrollees experienced incident dementia diagnosis. There were immediate increases in antipsychotic (0.9% [0.5, 1.4] absolute increase, p < 0.001) and antidepressant (4.0% [3.3, 4.6] absolute increase, p < 0.001) use in the month following diagnosis. Increased use of these medications peaked 3-5 years after diagnosis. Dementia diagnosis was associated with decreased slopes of opioid (- 0.2% [- 0.3, - 0.1], p < 0.001) and benzodiazepine (- 0.07% [- 0.11, - 0.03], p < 0.001) use. Conclusions: CNS-active medication use is higher in older adults with dementia when compared to those without dementia. Incident dementia diagnosis is accompanied by marked increases in the use of antidepressants and antipsychotics.
引用
收藏
页数:9
相关论文
共 38 条
  • [1] Are Chronic Pain Patients with Dementia Being Undermedicated?
    Achterberg, Wilco P.
    Erdal, Ane
    Husebo, Bettina S.
    Kunz, Miriam
    Lautenbacher, Stefan
    [J]. JOURNAL OF PAIN RESEARCH, 2021, 14 : 431 - 439
  • [2] [Anonymous], 2022, U.S. Opioid Dispensing Rate Maps | Drug Overdose
  • [3] [Anonymous], 2015, Conducting Interrupted Time-series Analysis for Singleand Multiple-group Comparisons-Ariel Linden, DOI [10.1177/1536867X1501500208, DOI 10.1177/1536867X1501500208]
  • [4] Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
    Banerjee, Sube
    Hellier, Jennifer
    Dewey, Michael
    Romeo, Renee
    Ballard, Clive
    Baldwin, Robert
    Bentham, Peter
    Fox, Chris
    Holmes, Clive
    Katona, Cornelius
    Knapp, Martin
    Lawton, Claire
    Lindesay, James
    Livingston, Gill
    McCrae, Niall
    Moniz-Cook, Esme
    Murray, Joanna
    Nurock, Shirley
    Orrell, Martin
    O'Brien, John
    Poppe, Michaela
    Thomas, Alan
    Walwyn, Rebecca
    Wilson, Kenneth
    Burns, Alistair
    [J]. LANCET, 2011, 378 (9789) : 403 - 411
  • [5] Barnes DE, 2012, ARCH GEN PSYCHIAT, V69, P493, DOI 10.1001/archgenpsychiatry.2011.1481
  • [6] Antiepileptic prescribing to persons living with dementia residing in nursing homes: A tale of two indications
    Candon, Molly
    Strominger, Julie
    Gerlach, Lauren B.
    Maust, Donovan T.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (01) : 89 - 97
  • [7] Psychotropic drug treatment for agitated behaviour in dementia: what if the guideline prescribing recommendations are not sufficient? A qualitative study
    Dijk, Margaretha T.
    Tabak, Sarah
    Hertogh, Cees M. P. M.
    Kok, Rob M.
    van Marum, Rob J.
    Zuidema, Sytse U.
    Sizoo, Eefje M.
    Smalbrugge, Martin
    [J]. AGE AND AGEING, 2022, 51 (09)
  • [8] Prescription Opioids and Risk of Dementia or Cognitive Decline: A Prospective Cohort Study
    Dublin, Sascha
    Walker, Rod L.
    Gray, Shelly L.
    Hubbard, Rebecca A.
    Anderson, Melissa L.
    Yu, Onchee
    Crane, Paul K.
    Larson, Eric B.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 (08) : 1519 - 1526
  • [9] Antidepressants for treating depression in dementia
    Dudas, Robert
    Malouf, Reem
    McCleery, Jenny
    Dening, Tom
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (08):
  • [10] Comorbidity measures for use with administrative data
    Elixhauser, A
    Steiner, C
    Harris, DR
    Coffey, RN
    [J]. MEDICAL CARE, 1998, 36 (01) : 8 - 27